J 2022

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

SCLAFANI, Francesco, Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE et. al.

Základní údaje

Originální název

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

Autoři

SCLAFANI, Francesco (garant), Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE, Elizabeth SMYTH, Mark PEETERS, Radka OBERMANNOVÁ (203 Česká republika, domácí), Cindy NEUZILLET, Manfred P LUTZ, Thibaud KOESSLER, Irit BEN-AHARON, Dirk ARNOLD, Maria ALSINA a Markus MOEHLER

Vydání

CLINICAL COLORECTAL CANCER, DALLAS, CIG MEDIA GROUP, LP, 2022, 1533-0028

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.400

Kód RIV

RIV/00216224:14110/22:00128356

Organizační jednotka

Lékařská fakulta

UT WoS

000898614900008

Klíčová slova anglicky

Clinical trials; Meeting; Esophago-gastric cancers; Hepato-pancreatico-biliary cancers; Colorectal cancers

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 30. 1. 2023 12:51, Mgr. Tereza Miškechová

Anotace

V originále

Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.